Moleculin Biotech
MBRX
22 hedge funds and large institutions have $4.26M invested in Moleculin Biotech in 2019 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 8 closing their positions.
0% less ownership
Funds ownership: 0% → 0% (-0%)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
17% less capital invested
Capital invested by funds: $5.16M → $4.26M (-$900K)
19% less funds holding
Funds holding: 27 → 22 (-5)
63% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$157K |
| 2 |
Renaissance Technologies
New York
|
+$74.9K |
| 3 |
BlackRock
New York
|
+$32.8K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$21.1K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$14K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$122K |
| 2 |
WIC
Whitegate Investment Counselors
Concord,
New Hampshire
|
-$51.5K |
| 3 |
Jane Street
New York
|
-$42K |
| 4 |
ARTA
A.R.T. Advisors
New York
|
-$31K |
| 5 |
HF
HRT Financial
New York
|
-$22K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PWMG
26
Prestige Wealth Management Group
Flemington,
New Jersey
| $1K | – | – | – |
|
|
27
Jane Street
New York
| – | -$42K | -17 | Closed |
|
|
ARTA
28
A.R.T. Advisors
New York
| – | -$31K | -13 | Closed |
|
|
HF
29
HRT Financial
New York
| – | -$22K | -9 | Closed |
|
|
CF
30
Centaurus Financial
Anaheim,
California
| – | -$11K | -4 | Closed |
|
|
LNWWM
31
Laird Norton Wetherby Wealth Management
San Francisco,
California
| – | -$11K | -4 | Closed |
|
|
SIM
32
Sonora Investment Management
Tucson,
Arizona
| – | -$11K | -4 | Closed |
|
33
Victory Capital Management
San Antonio,
Texas
| – | -$8K | -3 | Closed |
|
34
Rockefeller Capital Management
New York
| – | -$3K | -1 | Closed |
|
|
TRCT
35
Tower Research Capital (TRC)
New York
| – | -$1K | – | – |
|
MBRX Hedge Fund Activity: Q4 2019 in Review
22 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q4 2019, worth a combined $4.26M — down 17% from $5.16M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of MBRX and 3 opened new positions — a net loss of 5 holders — while 3 trimmed existing stakes and 3 added.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $157K. The largest seller was Millennium Management, cutting an estimated $122K.
- 22 institutional investors held Moleculin Biotech (MBRX) as of Q4 2019, down from 27 in Q3 2019.
- Funds reported $4.26M of Moleculin Biotech stock for Q4 2019, down 17% quarter-over-quarter.
- 3 funds opened new Moleculin Biotech positions in Q4 2019 and 8 closed out, a net change of -5 holders.
- The largest Moleculin Biotech buyer in Q4 2019 was Susquehanna International Group, an estimated $157K added.
- The largest Moleculin Biotech seller in Q4 2019 was Millennium Management, an estimated $122K sold.
Based on aggregated 13F filings for Q4 2019.